# Dr. Reddy's: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Dr. Reddy's Laboratories Limited · NSE: DRREDDY · BSE: 500124 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/dr-reddys. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Dr. Reddy's: how the business works", with the page URL.

## In short

Drug wholesalers, pharmacies, hospitals and other drug makers pay Dr. Reddy's for medicines and ingredients; materials take ₹34.9 of every ₹100, and ₹12.0 is profit.

- Customers in the US paid 35.1% of FY26 revenue, down from 45.9% in FY25, after US lenalidomide exclusivity ended in Jan 2026.
- Profit for shareholders fell 25.8% in FY26, to ₹4,196 crore, and fell 50.5% in H1 FY27 from a year earlier.

## Key facts

**What does Dr. Reddy's do?**

Dr. Reddy's Laboratories, based in Hyderabad, makes generic and branded medicines and their active ingredients. Dr. Reddy's sold in 87 countries in FY26, and its FY26 revenue from operations was ₹33,700 crore. [S1, S2, S11]

**How does Dr. Reddy's make money?**

Dr. Reddy's earns most of its money from finished medicines. Its Global Generics segment was 88.9% of FY26 revenue and earned ₹16,970 crore of Dr. Reddy's ₹17,728 crore gross profit. Active ingredients and services (PSAI) were 10.5% of revenue. [S1]

**Who are Dr. Reddy's customers?**

Dr. Reddy's sells to wholesalers, distributors, pharmacy chains, hospitals, government institutions and other drug makers. In FY26, customers in the US paid 35.1% of Dr. Reddy's revenue, India 19.2% and Russia 10.4%. Dr. Reddy's Indian filings do not disclose revenue by customer. [S1, S2]

**How big is Dr. Reddy's?**

In FY26 Dr. Reddy's consolidated revenue from operations was ₹33,700 crore and its profit for shareholders was ₹4,196 crore. Dr. Reddy's had 27,527 permanent employees and 24 manufacturing facilities in FY26. [S11, S1]

**Who owns Dr. Reddy's?**

On 30 Sep 2026 the promoter group, the families of K Satish Reddy and G V Prasad, held 26.63% of Dr. Reddy's, with no shares pledged. JP Morgan Chase Bank, depository for Dr. Reddy's US-listed ADRs, held 11.10% for ADR holders. Other foreign investors held 20.30%, Indian institutions 31.88% (LIC 12.14%) and individuals and others 9.90%. [S37, S1]

**Why was Dr. Reddy's FY26 profit lower than FY25?**

Dr. Reddy's FY26 profit for shareholders of ₹4,196 crore was 25.8% below FY25's ₹5,655 crore. US lenalidomide exclusivity ended in Jan 2026, and Q4 FY26 revenue carried a ₹453 crore lenalidomide shelf-stock adjustment. FY26 also included ₹352 crore of write-downs (impairments). [S11, S12, S38]

**Does Dr. Reddy's have debt?**

On 30 Sep 2026 Dr. Reddy's had ₹5,826 crore of borrowings and ₹6,874 crore of cash, bank balances and short-term investments. ICRA rated Dr. Reddy's AA+ with a stable outlook on 9 Jan 2026. [S3, S38]

**What dividend did Dr. Reddy's pay for FY26?**

Dr. Reddy's board recommended a final dividend of ₹8 per share for FY26 on 12 May 2026. That was 15.9% of Dr. Reddy's FY26 basic earnings per share of ₹50.41 (Cityfort calculation). [S12, S11]

**Where are Dr. Reddy's shares listed?**

Dr. Reddy's shares trade on the NSE as DRREDDY and on the BSE as 500124. Dr. Reddy's American depositary receipts (ADRs) trade on the New York Stock Exchange as RDY. [S3, S4]

## What does Dr. Reddy's sell?

Dr. Reddy's makes medicines and sells them in 87 countries. Most are generics: copies of medicines whose patents have ended. It also sells branded medicines in India and active ingredients to other drug makers.

- **Generic medicines for North America:** Copies of off-patent medicines sold in the US and Canada. The company's figure (IFRS) for FY26 was ₹11,374 crore, down 22% from FY25. [S12]
- **Branded medicines in India:** Medicines sold in India under Dr. Reddy's brand names, including Obeda semaglutide from Mar 2026. The company's figure for FY26 was ₹6,219 crore, up 16%. [S12, S64]
- **Emerging markets:** Medicines sold in Russia, other CIS countries and the rest of the world. The company's figure for FY26 was ₹6,761 crore, up 23%. [S12]
- **Europe, including nicotine gums:** Generics in Germany, the UK and other countries, plus nicotine replacement brands such as Nicotinell bought from Haleon. The company's figure for FY26 was ₹5,550 crore, up 55%. [S12, S38, S5]
- **Active ingredients and services (PSAI):** Active pharmaceutical ingredients (APIs, the chemicals that make a medicine work) and contract services for other drug makers. The company's figure for FY26 was ₹3,477 crore. [S12, S1]
- **Biosimilars and partner products:** Biosimilars are near-copies of medicines made from living cells. An abatacept biosimilar awaits US approval. On 18 Sep 2026 Dr. Reddy's signed an agreement to distribute Takeda's dengue vaccine Qdenga in India's private market, with launch planned for H1 2027. [S6, S69, S5]

## Who pays Dr. Reddy's?

- **Buyers of finished medicines (88.9% of revenue):** Wholesalers, distributors, pharmacy chains, hospitals and government institutions buying the Global Generics segment's medicines. Share is of FY26 revenue. [S1, S2]
- **Other drug makers (10.5% of revenue):** Buy active ingredients and contract research and manufacturing services (PSAI segment). Share is after removing PSAI's sales to Dr. Reddy's own generics business. [S1, S2]
- **Others (0.6% of revenue):** Aurigene Oncology (a drug discovery business) and proprietary products. [S1]
- **Customer concentration:** The Indian filings do not disclose revenue by customer. The FY26 BRSR lists customer types only. [S1, S2]

## Where the money went (FY26)

1. In FY26 Dr. Reddy's sold ₹33,700 crore of medicines, ingredients and services, and had ₹1,358 crore of other income.
2. Materials and goods bought took ₹12,239 crore, and employees ₹5,991 crore.
3. Other running costs took ₹9,017 crore, including ₹352 crore of write-downs (impairments).
4. Depreciation took ₹2,059 crore, interest ₹374 crore and income tax ₹1,235 crore.
5. What was left for Dr. Reddy's shareholders was ₹4,196 crore of profit.

Sources: S11.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 21,545 | 3,768 | 17.5% | 2,183 | 10.1% | 26.24 | 2,811 | 1,905 | 906 | S25 |
| FY23 | 24,670 | 6,349 | 25.7% | 4,507 | 18.3% | 54.18 | 5,887 | 1,886 | 4,001 | S24, S23 |
| FY24 | 28,011 | 7,933 | 28.3% | 5,578 | 19.9% | 66.92 | 4,543 | 2,744 | 1,800 | S22, S20 |
| FY25 | 32,644 | 8,547 | 26.2% | 5,655 | 17.3% | 67.79 | 4,643 | 3,440 | 1,203 | S19, S1 |
| FY26 | 33,700 | 6,454 | 19.1% | 4,196 | 12.5% | 50.35 | 5,674 | 3,841 | 1,833 | S11, S1, S12 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.
- FY26: Minority partners bore ₹38 crore of losses, so profit for Dr. Reddy's shareholders is above total profit.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Dr. Reddy's cash and short-term investments were ₹1,048 crore more than its borrowings (Cityfort calculation from the Q2 FY27 results). [S3, S5, S6, S19, S22, S38]

| Item | Value |
| --- | --- |
| Total debt | 5,826 |
| Cash and investments | 6,874 |
| Net debt (debt minus cash) | −1,048 |
| Net worth (shareholders' money) | 38,807 |
| Debt to equity (times) | 0.15 |
| Interest cover (times) | 8.1 |

- Cash and short-term investments = cash, other bank balances and current investments. All borrowings were short-term.
- Lease liabilities (rent owed under leases) were a further ₹1,403 crore; counting them, debt exceeded cash by ₹355 crore (Cityfort calculation).
- The company reports a "net cash surplus" of ₹2,502 crore on its own IFRS definition, which adjusts for non-current cash and borrowings.
- Borrowings rose from ₹1,652 crore on 31 Mar 2024 to ₹4,185 crore a year later, the year it bought the nicotine replacement business from Haleon.
- Interest cover = (profit before tax + interest) ÷ interest, H1 FY27 (Cityfort calculation). Debt to equity = borrowings ÷ total equity.

## Who owns Dr. Reddy's? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 26.63% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 20.3% |
| Indian institutions (DII) | 31.88% |
| Public | 9.9% |
| Shares behind US-listed ADRs (held by JP Morgan Chase Bank as depository; filed inside foreign institutions) | 11.1% |

Sources: S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S42.

## What could go wrong

### Price competition in US generics

US customers paid 35.1% of FY26 revenue, down from 45.9% in FY25. After lenalidomide exclusivity ended in Jan 2026, North America revenue fell 23% in Q2 FY27 (company figure). ICRA lists US generics price competition as a challenge. [S1, S5, S38]

What to watch: North America revenue each quarter (₹2,489 crore in Q2 FY27, company figure).

### US FDA inspection findings

Plants that supply the US must pass US FDA inspections. As of 11 Nov 2026 the company had disclosed four inspections with Form 483s and one records assessment (Form FDA 2953) with no final classification, including 7 observations at its biologics plant in Jun 2026. [S48, S52, S53, S54, S57]

What to watch: FDA classification of the open inspections, and any warning letter or import alert.

### Semaglutide supply problem

On 9 Jul 2026 the company said semaglutide batches failed specification because of an ingredient (API) issue. Q1 FY27 carried a ₹239.7 crore provision for inventory and related costs. [S41, S8, S6]

What to watch: Whether semaglutide supplies resume, and semaglutide sales in Q3 and Q4 FY27.

### Pending US antitrust lawsuits

US class actions allege price-fixing of generic medicines, and other suits make antitrust claims over Revlimid (lenalidomide). The company says most amounts cannot be reasonably estimated and has made no provision. [S1, S38]

What to watch: Court rulings, and any provision in the results notes.

### Russia taxes and exposure

Customers in Russia paid 10.4% of FY26 revenue. FY26 included Russian VAT provisions of ₹69.5 crore in Q2 and ₹114.1 crore in Q4. [S1, S12, S5]

What to watch: Russia revenue (₹1,008 crore in Q2 FY27, company figure) and any new tax provisions.

### Weaker cash flow in H1 FY27

Operating cash flow was ₹435 crore in H1 FY27, against ₹3,020 crore in H1 FY26. After ₹802 crore of capex, free cash flow was −₹367 crore. [S3, S17, S6]

What to watch: Operating cash flow in the H2 FY27 results.

### Write-downs on research bets

FY26 included ₹352 crore of write-downs, among them ₹129.1 crore for a stopped CAR-T programme and ₹91.4 crore for eftilagimod alfa, whose Phase III trial was stopped for futility. [S12, S62, S11]

What to watch: Impairment charges in each quarter's results.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Semaglutide re-launch:** Management said on the Q2 FY27 call (23 Oct 2026) it expected to re-launch semaglutide in November 2026, subject to validation; on 22 Jul 2026 it spoke of 6 to 7 million pens between November and March.
- **US FDA outcomes:** The biologics plant got 7 observations in a Jun 2026 pre-licence inspection, and the abatacept biosimilar awaits US approval.
- **North America after lenalidomide:** North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier (company figure). Q3 FY26 results were filed on 21 Jan 2026.

## Sources

- S1: Integrated Annual Report FY2025-26. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_30062026194205_Integrated_Annual_Report_signed.pdf (published 30 Jun 2026)
- S2: Business Responsibility and Sustainability Report FY2025-26. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_30062026193546_BRSR_signed.pdf (published 30 Jun 2026)
- S3: Q2 FY27 consolidated financial results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1744951_23102026064928_WEB.xml (published 23 Oct 2026)
- S4: Q2 FY27 results filing: board outcome and financial results (PDF). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_23102026172921_SE_Intimation_results_23102026.pdf (published 23 Oct 2026)
- S5: Q2 FY27 results presentation (IFRS). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_23102026173751_SEintimation_Investor_presentation_23102026_1.pdf (published 23 Oct 2026)
- S6: Q2 FY27 earnings call transcript (23 Oct 2026). Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 29 Oct 2026). https://www.drreddys.com/cms/sites/default/files/2026-10/EarningsCallTranscriptQ2FY27.pdf (published 29 Oct 2026)
- S7: Q1 FY27 consolidated financial results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1699536_22072026064701_WEB.xml (published 22 Jul 2026)
- S8: Q1 FY27 results filing (PDF, notes). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_22072026161515_SE_Intimation_Outcome_results_22072026_1.pdf (published 22 Jul 2026)
- S9: Q1 FY27 results presentation (IFRS). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_22072026164806_SEintimation_Investor_presentation_22072026.pdf (published 22 Jul 2026)
- S10: Q1 FY27 earnings call transcript (22 Jul 2026). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_28072026230947_SE_Intimation_Transcript_of_earning_call_recordings_3_signed.pdf (published 28 Jul 2026)
- S11: Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1666026_12052026053708_WEB.xml (published 12 May 2026)
- S12: Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_12052026163727_SEintimation_Outcome_of_BM_12052026_signed.pdf (published 12 May 2026)
- S13: Q4 FY26 earnings call transcript (12 May 2026). Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 18 May 2026). https://www.drreddys.com/cms/sites/default/files/2026-05/DRL_Q4FY26EarningsCall%20Transcript_12May2026.pdf (published 18 May 2026)
- S14: Q3 FY26 consolidated financial results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1607669_21012026073112_WEB.xml (published 21 Jan 2026)
- S15: Q3 FY26 results filing (PDF, press release and notes). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_21012026165722_SE_Intimation_Outcome_of_BM.pdf (published 21 Jan 2026)
- S16: Q3 FY26 earnings call transcript (21 Jan 2026). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_27012026224754_SE_intimation_transcript_of_earnings_call_signed.pdf (published 27 Jan 2026)
- S17: Q2 FY26 consolidated financial results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1556724_24102025113222_WEB.xml (published 24 Oct 2025)
- S18: Q1 FY26 consolidated financial results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1491661_23072025065639_WEB.xml (published 23 Jul 2025)
- S19: Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1435419_09052025093151_WEB.xml (published 9 May 2025)
- S20: Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_09052025164909_SEintimation09052025_Outcome_Results_final.pdf (published 9 May 2025)
- S21: Q3 FY25 consolidated financial results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_117600_1360097_24012025015557.xml (published 24 Jan 2025)
- S22: Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_105407_1117456_07052024082051.xml (published 7 May 2024)
- S23: Q4 FY24 results filing (PDF; FY23 comparatives). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/SEintimation07052024_Outcome_Results_07052024161101.pdf (published 7 May 2024)
- S24: Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_91495_840393_10052023074616.xml (published 10 May 2023)
- S25: Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_84804_656860_19052022050401_WEB.xml (published 19 May 2022)
- S26: Shareholding pattern as of Dec 2023 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_184913_1028613_19012024124750_WEB.xml (published 19 Jan 2024)
- S27: Shareholding pattern as of Mar 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_187695_1099922_19042024112352_WEB.xml (published 19 Apr 2024)
- S28: Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_189744_1194797_19072024044224_WEB.xml (published 19 Jul 2024)
- S29: Shareholding pattern as of Sep 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_193441_1282548_21102024035855_WEB.xml (published 21 Oct 2024)
- S30: Shareholding pattern as of Dec 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_196056_1356539_21012025101621_WEB.xml (published 21 Jan 2025)
- S31: Shareholding pattern as of Mar 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_198504_1420290_19042025083556_WEB.xml (published 19 Apr 2025)
- S32: Shareholding pattern as of Jun 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1488636_21072025024231_WEB.xml (published 21 Jul 2025)
- S33: Shareholding pattern as of Sep 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1549860_16102025125032_WEB.xml (published 16 Oct 2025)
- S34: Shareholding pattern as of Dec 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1605123_20012026121208_WEB.xml (published 20 Jan 2026)
- S35: Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1698187_21072026033805_WEB.xml (published 21 Jul 2026)
- S36: Shareholding pattern as of Jun 2026 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1698407_21072026050510_WEB.xml (published 21 Jul 2026)
- S37: Shareholding pattern as of Sep 2026 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1742881_21102026034106_WEB.xml (published 21 Oct 2026)
- S38: ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable). ICRA Ltd. https://www.icra.in/Rating/GetRationalReportFilePdf?id=140199 (published 9 Jan 2026)
- S39: Credit rating intimation: ICRA reaffirms [ICRA]AA+ (Stable), bank limits ₹2,000 crore. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_27122024180021_SE_CreditRating_27122024final.pdf (published 27 Dec 2024)
- S40: NSE capital market bhavcopy, 11 Nov 2026 (DRREDDY EQ close). National Stock Exchange of India. https://nsearchives.nseindia.com/content/cm/BhavCopy_NSE_CM_0_0_0_20261111_F_0000.csv.zip (published 11 Nov 2026)
- S41: Intimation: semaglutide batches out of specification due to API issue; supplies delayed. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_09072026091837_SE_intimation_09072026.pdf (published 9 Jul 2026)
- S42: Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_18092025204029_SE_Intimation_18092025_2.pdf (published 18 Sep 2025)
- S43: Disclosure: US SEC concludes FCPA investigation, no enforcement recommended. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_24022026173149_SEIntimation.pdf (published 24 Feb 2026)
- S44: Disclosure: US DOJ closes FCPA inquiry. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_06032026171520_SE_Intimation_-_DOJ_060326_signed.pdf (published 6 Mar 2026)
- S45: Press release: intention to appoint Deloitte Haskins & Sells LLP as statutory auditors from FY2026-27. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_23072025164845_DRL_SE_intimation_Deliotte.pdf (published 23 Jul 2025)
- S46: AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_23072026211951_SEintimation_Regulation_30_Director_and_Stat_Auditor_signed.pdf (published 23 Jul 2026)
- S47: Intimation: Post-Application Action Letter from US FDA for biologics facility, Bachupally. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_10012026193352_SEintimation_10012026.pdf (published 10 Jan 2026)
- S48: Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_25062026223935_SE_intimation_25062026_signed.pdf (published 25 Jun 2026)
- S49: Intimation: US FDA classifies API Mirfield (UK) inspection as VAI. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_14082026231157_SE_intimation_14082026_signed.pdf (published 14 Aug 2026)
- S50: Intimation: US FDA PAI and GMP inspection at FTO-SEZ Process Unit-02, Srikakulam: Form 483 with 3 observations. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_29072026214004_SE_intimation_29072026_signed.pdf (published 29 Jul 2026)
- S51: Intimation: US FDA classifies FTO-SEZ Process Unit-02 inspection as VAI. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_28102026183625_SE_intimation_28102026_signed.pdf (published 28 Oct 2026)
- S52: Intimation: US FDA GMP inspection at formulations facility FTO-3, Bachupally: Form 483 with 4 observations. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_14082026233205_SE_intimation_14082026-Bachupally.pdf (published 14 Aug 2026)
- S53: Intimation: US FDA records assessment at API facility, Mexico: Form FDA 2953 with 2 observations. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_11092026220841_SE_intimation_11092026_signed.pdf (published 11 Sep 2026)
- S54: Intimation: US FDA PAI at FTO-11, Pydibhimavaram: Form 483 with 2 observations. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_08102026155720_SE_intimation_08102026_signed.pdf (published 8 Oct 2026)
- S55: Intimation: resignation of Deepak Sapra, CEO API and Services. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_13082026164551_Stock_Exchange_intimation_dated_13082026.pdf (published 13 Aug 2026)
- S56: Intimation: appointment of Akhil Ravi as Head API and Services. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_23102026184253_SE_intimation_Reg30_change_in_mgt_23102026_Signed.pdf (published 23 Oct 2026)
- S57: Intimation: US FDA PAI at FTO-9, Visakhapatnam: Form 483 with 3 observations. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_14102026201614_SE_intimation_14102026_signed.pdf (published 14 Oct 2026)
- S58: Intimation: US FDA Complete Response Letter for AVT03 (denosumab) BLA. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_31122025195143_DRL_SE_Intimation_31122025.pdf (published 31 Dec 2025)
- S59: Intimation: final tax penalty decision for Russian subsidiary. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_14042026211714_DRL_SE_intimation_signed.pdf (published 14 Apr 2026)
- S60: Intimation: IRS penalty on US subsidiary Dr. Reddy's Laboratories, Inc.. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf (published 3 Oct 2026)
- S61: Disclosure: acquisition of the STUGERON portfolio from Janssen. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_10092025232254_DRL_SE_intimation_10092025.pdf (published 10 Sep 2025)
- S62: Disclosure: Immutep update on TACTI-004 Phase III (eftilagimod alfa). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_13032026184038_Immutep_SE_Disclosure_F_signed.pdf (published 13 Mar 2026)
- S63: Disclosure: acquisition of Progynova and Cyclo-Progynova trademarks for India. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_18022026194041_DRLSEintimation_18022026.pdf (published 18 Feb 2026)
- S64: Press release: launch of semaglutide injection (Obeda) in India. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_21032026135945_DRLSEIntimation_PR_21032026_signed.pdf (published 21 Mar 2026)
- S65: Disclosure: sale of wholly owned subsidiary Svaas Wellness Ltd. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_07042026193545_SE_intimation_for_sale_of_svaas_signed.pdf (published 7 Apr 2026)
- S66: Disclosure: Health Canada Notice of Compliance for semaglutide injection. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_29042026091107_DRL_SE_intimation_29th_Apr_2026.pdf (published 29 Apr 2026)
- S67: Press release: launch of generic semaglutide injection in Canada. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_16052026002733_DRL_SE_intimation_PR_Signed.pdf (published 16 May 2026)
- S68: Intimation: termination of distribution agreement with Novartis India. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_07082026225902_SE_intimation_070826_signed.pdf (published 7 Aug 2026)
- S69: Disclosure: exclusive distribution agreement with Takeda for Qdenga (India private market). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_18092026090427_DRL_SE_intimation_18092026_signed.pdf (published 18 Sep 2026)
- S70: Press release: marketing authorization for generic semaglutide injection in Brazil. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_05112026095128_DRL_SE_intimation_signed.pdf (published 5 Nov 2026)
- S71: AGM 24 Jul 2025 outcome: re-appointment of G V Prasad as Co-Chairman and MD. Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_24072025220056_SEIntimation_Director_appointment_24072025.pdf (published 24 Jul 2025)
- S72: Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/09/SPIL-IR-Presentation-Sept-2026-INR-1.pdf (published 22 Sep 2026)
